📋 Tender Overview
With todays official opening of the Startup Labs Vienna the Life Science location Vienna is setting new Austria-wide standards in the provision of infrastructure for young research companies. From now on new cancer therapies and drugs against infectious diseases such as Covid19 will be developed at the Vienna BioCenter in the third district of Vienna on 1100 m2. Nine relevant startups have already moved into the laboratory space. Vienna is one of the top 5 life science locations in Europe. With the opening of the Startup Labs Vienna we can maintain our position among the top European research leaders in the long term said the Vienna City Councilor for Economic Affairs Peter Hanke adding By providing this state-of-the-art infrastructure the startup teams can concentrate on their core tasks immediately and get started faster.A total of 60 laboratory workplaces combined with 30 office workplaces are available for researchers at the Vienna Bio Center. The core of this is the so-called share principle. By sharing the laboratory equipment provided such as sterile workbenches nitrogen tanks bacterial shakers or a laundry room for the sterilization of laboratory materials startups can avoid costly investments. This saves time and money as the researchers can invest all resources directly into developing their products. Boehringer Ingelheim is also showing extraordinary commitment with its Innovation Prize. Cooperation with startups from the life science community is an important element in Boehringer Ingelheims research strategy. We hope to find interesting food for thought and points of contact to our scientists on various levels says Dr. Guido Boehmelt Head of Research Beyond Borders at Boehringer Ingelheim RCV . Boehringer Ingelheim is the main sponsor of the Startup Labs and uses the BI Innovation Prize to finance selected startups for laboratory and office jobs for one year each. The first winner of the BI Innovation Prize is Proxygen. The company has developed a new molecular principle that allows proteins that were previously considered untreatable to be efficiently removed. This is achieved through a special type of small molecule that can reprogram the natural degradation machinery of cells in order to specifically break down those proteins that are the main cause of diseases such as cancer. Proxygen is thus breaking new ground in this field of science. The Vienna BioCenter is a Europe-wide blend of cutting-edge biomedical research educational opportunities and an innovative entrepreneurial spirit says Harald Isemann Commercial Director of the Research Institute for Molecular Pathology IMP and Chairman of the Vienna BioCenter . In the last 10 years we have seen dynamic growth from a handful to currently 35 biotech companies. With the Startup Labs we are now in the best possible position to accelerate this positive development even further. Excellence in Vienna as a science locationVienna has an excellent scientific tradition in biomedical research and has been growing steadily for years. 554 companies and research institutions employ over 37500 people in the life sciences in Vienna. The companies generated around 12.2 billion euros in sales in 2017.
